Projected Sales Volume: Ascentage Pharma (AAPGV)

Corporate company logo of Ascentage Pharma Group (AAPGV)

Ascentage Pharma Group is implementing robotic systems to accelerate the discovery of anti-tumor agents. The company's revenues are based on the licensing of small molecules and successes in cancer therapy, while the GURU.Markets portal features a price action chart in the form of a projected sales volume for the company, where 0.09 expresses the latest metric level. High R&D expenditures and patents for apoptosis inhibitors create a robust defensive barrier.

Company Future Sales: Ascentage (AAPGV) for 01/25/2025 - 11/16/2026

Summary analytical data breakdowns for Ascentage (AAPGV)

- stock quotes and analyst forecast:
- company stock exchange capitalization indicators:
Summary company analytics:Ascentage Pharma Group AAPGV
Brand item of Ascentage Pharma Group Ltd

Ascentage Pharma Group (AAPGV) is developing innovative apoptosis inhibitors to combat resistant forms of leukemia. This indicator measures expected revenue by synthesizing global economic trends and market expectations into a daily value. By analyzing the dynamics of the company's prospective sales, investors assess the impact of lisonaclax's success and the partnership with Takeda on capitalization. Steady growth in the trendline confirms fundamental support for the asset. However, a sharp rally without corrections signals overbought conditions and the risk of a collapse upon a cycle shift.

Key competitors

Projected Sales Volume ONC|HALO (Halozyme) - Company Future Revenue|Projected Sales Volume RVMD (revmed.com)|Company Future Sales Ascentage (AAPG)|CGON: Company Future Sales Volume|Company Expected Sales Volume UroGen Pharma Ltd.|BCAX: Projected Sales Volume|PSNL - Company Future Sales|ERAS (Erasca Oncology) - Projected Sales Volume|Projected Sales Volume Delcath Systems, Inc.|Company Projected Revenue ymabs.com (YMAB)|Company Projected Revenue AURA (Aura Biosciences, Inc.)|Candel Therapeutics - Company Future Sales Volume|Accuray Inc. (ARAY) - Company Expected Sales Volume|SELLAS Life Sciences Group, Inc. - Projected Sales Volume|Company Future Revenue ACTU (Actuate Therapeutics, Inc.)|Citius Oncology (CTOR) - Company Projected Revenue|HURA - Company Future Sales|TARA (Protara Therapeutics, Inc.) - Projected Sales Volume|Projected Sales Volume Fate Therapeutics Inc|Projected Sales Volume WHWK|Projected Sales Volume TScan Therapeutics Inc (TCRX)|Company Projected Revenue championsoncology.com CSBR|XBIT - Company Future Sales Volume|CVM - Company Projected Revenue|Company Future Revenue OSTX (OS Therapies)|RADX: Projected Sales Volume|Artiva Biotherapeutics Inc. - Company Future Revenue|ANL (Adlai Nortye) - Projected Sales Volume|Projected Sales Volume verupharma.com|Company Future Sales Volume TPST (tempesttx.com)|Company Future Sales Volume Xilio Therapeutics Inc XLO|Projected Sales Volume RENB (Enochian BioSciences)|Mural Bio - Company Projected Revenue|KAPA - Company Projected Revenue|OnKure Therapeutics (OKUR) - Company Future Sales Volume|GDTC: Projected Sales Volume|Company Expected Sales Volume Curis Corp (CRIS)|APLM (apollomicsinc.com) - Projected Sales Volume|Company Future Sales Volume Tharimmune Corp (THAR)|Projected Sales Volume ADVB|GNPX - Company Expected Sales Volume|Company Projected Revenue calidibio.com CLDI|SBFM - Company Future Sales Volume|XBIO - Company Projected Revenue|SLRX: Company Projected Revenue|Purple Biotech (PPBT) - Company Projected Revenue|AON - Company Future Revenue|Company Future Sales Volume BGNE|Projected Sales Volume Checkpoint Therapeutics Inc.|Projected Sales Volume ELEV|Company Future Sales Volume iCAD ICAD|Projected Sales Volume IKNA (Ikena Oncology, Inc.)|Company Future Revenue NTBL|Viracta Therapeutics, Inc. - Projected Sales Volume|Company Future Revenue MOR (MorphoSys Inc)|NAYA (NAYA Biosciences Inc) - Company Future Sales Volume